Radioimmunolocalisation (RIL) has the potential to specifically differentiate between malignant and benign tissues. Studies in gastrointestinal cancer with antibodies to CEA have demonstrated correct identification in nearly 90% (Goldenberg et al., 1980) and 42% (Mach et al., 1980 ) of tumour sites. The variation between these series reflects differences in the subjective interpretation of the scans. In addition in these early studies polyclonal antibodies were investigated which are limited by cross-reactivity with similar antigens present in normal tissues. The development of monoclonal antibodies (Kohler & Milstein, 1975) has produced agents with theoretically greater specificity for the antigens and thus reduce the difficulties of crossreactivity. In this study we describe our experience with a radiolabelled monoclonal antibody to CEA together with its potential clinical application for the staging of primary gastric and colorectal cancer and for the detection of recurrent cancer. Previous studies have suggested that the actual amount of antibody accumulated in tumours is an extremely small proportion of the amount injected (Mach et al., 1981) and we have also assessed the distribution of labelled antibody in patients and measured the concentration of antibody within resected tumours.
Materials and methods

Preparation of labelled antibody
Monoclonal antibody 11-285-14 Surgical Immunology Unit of the Queen Elizabeth Hospital and Eli Lilly by conventional methods against CEA extracted from liver metastases from a colorectal carcinoma (Woodhouse, 1982) . Extensive characterisation has shown reaction with some normal and the majority of malignant gastrointestinal epithelium , Crowson et al., 1984 but no reactivity with a wide range of other normal tissues. In addition there is no reactivity with granulocytes, red blood cells, peripheral blood lymphocytes or chronic myeloid leukaemic cells. Animals studies with colorectal cancer xenografts in nude mice have demonstrated preferential accumulation of labelled antibody in tumours when compared with a control nonspecific antibody (unpublished observations, Pimm et al., 1985b) .
Approximately 500 g of antibody solution were labelled with 5mCi of 131 Iodine by the chloramine T method to a mean specific activity of 2.34,uCi/,ug. (Hunter & Greenwood, 1962) . All labelled preparations were tested for sterility and the absence of pyrogens prior to administration to patients. In addition anti-CEA activity was assessed after labelling by an enzyme linked immunosorbent assay (ELISA) (Woodhouse et al., 1981) and by indirect immunoperoxidase staining (Heyderman & Neville, 1977) and demonstrated a mean percentage loss in activity of 10%.
Patients
The details of the 50 patients investigated are shown in Table I . The diagnosis of primary disease was by conventional methods and of recurrent disease either by the development of new symptoms or an elevated serum CEA level. All patients gave Examination of resected specimens The radioactivity in samples of normal stomach or colon, tumour, lymph nodes and apparently normal tissues incidentally removed was measured in a well gamma counter (Nuclear Enterprises Scaler/Ratemeter SR7). In addition the complete specimen was scanned with the gamma camera.
In order to estimate the concentration of antibody within samples of the resected tumours, tumour tissue was homogenised in the presence of lysing buffer (20mm TRIS, 100mm NaCl, 1 mM EDTA and 0.5 nonidet P-40 pH8) and the antibody extracted by Sepharose-Protein A absorption. The concentration of antibody in the resultant suspension was determined by an ELISA. The total amount in the tumour was then estimated from the dimensions of the whole tumour.
Evaluation of vascular distribution and excretion
The intravascular distribution of the radiolabelled antibody has been assessed by estimating the circulating radioactivity and by measuring the circulating concentration of antibody at 6, 24, 48 and 72h. Radioactivity within 10ml samples of whole blood was measured and the activity in the total blood volume calculated and expressed as a percentage of the injected dose. The concentration of the antibody in serum was measured using an ELISA (as in the estimation of the concentration of the tumour samples).
Excretion of radioactivity in both urine and faeces was estimated for 24h periods and expressed as a percentage of the injected amount of radiation.
Results
Adverse reactions
Significant responses to the i.d. injection (tenderness and erythema greater than 1 cm in diameter) were observed in 3 patients at 24h. These patients did A typical scan from a patient with transverse colon cancer with spread to a local lymph node is shown in Figure 1 . The unsubtracted antibody scan shows increased activity in the upper abdomen. After thresholding there was an additional area of activity considerably smaller than the main lesion which was considered to be consistent with lymph node metastases. At laparotomy the primary lesion was confirmed, as was a 4cm diameter lymph node deposit in the transverse mesocolon.
Antibody scanning in the detection of recurrent cancer Twenty of the 24 evaluable patients (2 were excluded because of a significant skin reaction) had recurrent disease confirmed in 23 sites by second look laparotomy (n = 12) or by review of clinical progress (n = 12).
Antibody scanning and CT each identified 14 sites correctly but equally failed to detect 9 and 8 sites respectively (Table III) . The majority of the sites that were missed were small deposits, although in 2 cases bulky local recurrences were later removed at second look laparotomy. Four patients free of disease were correctly identified by CT, however antibody scanning suggested that 2 of these had recurrence. In a further 2 patients antibody scanning correctly identified recurrence but also suggested deposits in sites which were not later confirmed. Antibody scanning did detect disease in 2 patients which was not visible on CT scanning. One patient, who had undergone a gastrectomy 18 months previously for a node positive tumour, was investigated for recurrent symptoms. CT demonstrated ascites only whereas antibody scanning demonstrated uptake in both the liver and the original left hypochondrial incision (Figure 2 ). This patient rapidly developed clinical evidence of hepatic metastases and aspiration cytology of the original incision revealed adenocarcinoma cells. The second patient had undergone a Hartmann's procedure for a perforating carcinoma of the colon and had returned for reversal of his colostomy. CT was normal but antibody scanning revealed activity low in the pelvis which at laparotomy was confirmed to be due to many small deposits within the pelvic peritoneum and omentum.
Comparison of these two techniques demonstrates similar sensitivities (Table IV) . The relatively high false positive rate of the antibody scan however indicates limited specificity which is further reflected in the poor predictive value of a negative test. Examination of the resected specimens The radioactivity in samples of the resected tumour was consistently higher than in surrounding normal stomach or colon, or non CEA expressing tissues ( Table V) . Accumulation of activity by the oesophageal lesions was not significantly greater than surrounding normal oesophageal tissue. The uptake of activity by histologically involved lymph nodes was significantly greater than in normal lymph nodes removed with specimens of gastric cancer (Table V) . Those lymph nodes involved by primary colorectal lesions also had higher activity, but because of the small number of nodes examined, the difference from normal nodes did not reach statistical significance.
Examination of the resected diverticular mass demonstrated levels of radioactivity comparable to those obtained from tumours and this would presumably explain the positive antibody scan.
Confirmation of uptake of radioactivity was obtained by gamma camera scanning of the complete resected specimen. A typical scan and the associated tumour is shown in Figure 3 . This is from a patient with a carcinoma of the fundus of the stomach who had no lymph node metastases. The scan clearly demonstrates higher activity corresponding to the site of the lesion.
The ratios of the counts recorded for the tumours and the surrounding tissue were 1.9:1 for gastric cancer, 2.0:1 for colorectal cancer and 1.3:1 for oesophageal cancer. These ratios are lower than for tumour samples (Table V) reflecting attenuation of the counts from tissue which was at varying distances from the gamma camera crystal when the tumour, which was often rigid, was laid open.
The concentration of antibody within tumours was estimated in 3 of the resected colonic cancers. Each had significantly higher levels of radioactivity than surrounding normal tissue. The proportion of the injected amount of antibody present was 0.02%, 0.02% and 0.03% respectively. In order to determine possible cross-reactivity between normal human immunoglobulin within tumours and the antimouse immunoglobulin used in the assay, a tumour sample from a patient who had not received the labelled antibody was included in the Antibody concentration, however, showed a more dramatic decline. At 6 h the mean serum concentration was 2.8ngml-1 or 3.2% of the injected dose of antibody. By 24 h, the mean concentration was 1.9ngml-1 and by 48h only 3 patients had detectable levels with a mean concentration of 1.3 ng ml. -1 Excretion of radioactivity in the urine throughout each 24h period was the same: 8.6% +10.6 (day 1), 8.4% +9.0 (day 2) and 7.5% +5.0 (day 3). Thus 72h after labelled antibody infusion, 25% of the radioactivity had been excreted.
Excretion in the faeces, however, was minimal. After 24h 0.09 +0.14 of the injected activity was excreted and in the second 24h 0.13 +0.16 were excreted.
Discussion
RIL is potentially a tumour specific method of investigation. At present because a tumour specific antigen has yet to be identified, the technique depends on quantitative differences in the expression of antigens, such as CEA, between tumour and normal tissues. In this study we have evaluated potential clinical roles for RIL in the management of gastric and colorectal cancer. Although the scans have been interpreted by one of the investigators with prior knowledge of the extent of disease, independent assessment was not considered of value as not only does the technique remain to be standardised but potential sources of error are yet to be eliminated.
The results of the scans are comparable with reported series. Most of the primary tumours and the majority of the established recurrences have been detected. However, the experience of this and other studies demonstrates that tumour size is a significant limiting factor. Although some of the nodal secondary deposits were identified, scanning resolution was insufficient to allow reliable detection of small tumour volumes for accurate preoperative staging or for the detection of early recurrent disease. This limit of resolution, however, is no worse than for CT as the comparative study demonstrates similar numbers of false negative scans for either modality reflecting the failure to detect small lesions.
The measurement of radioactivity within tumours has indicated that both primary and secondary lesions accumulate more labelled antibody than surrounding normal tissues. The amount accumulated, however, is so low that detectable contrast from normal tissues cannot be reliably achieved by external scanning. Attempts to increase the tumour to normal tissue contrast have evaluated different isotopes (Fairweather et al., 1983b; Rainsbury, 1984) and different methods of scanning such as emission tomography (Berche et al., 1982) . These techniques, however, are methods of improving the sensitivity of the detection of the very small amounts of labelled antibody accumulated by tumours. In order for tumour localisation to be effective for both diagnostic imaging and for drug targetting, larger proportions of injected antibody need to be accumulated. Preliminary studies have demonstrated that combinations of antibodies to different antigens increase the rate of detection of tumours presumably reflecting increased uptake of the injected preparations (Chatal et al., 1984) . Alternatively, increased amounts of antibody to the same antigen may produce similar results. The presently available antibodies are not ideal and it remains to be seen whether more appropriate antibodies either in combination or in larger doses will improve the results of tumour localisation.
The pharmacokinetic studies indicate potentially significant difficulties for the use of mouse monoclonal antibodies. Previous studies of labelled autologous gamma globulin have demonstrated a biphasic clearance over a period of fourteen days (Myant, 1952) . The results of this study for the vascular distribution of radioactivity are in concurrence with these studies. However the rapid clearance of antibody suggests that radioactivity changes are not a reflection of changes in antibody levels. The reasons for this apparent discrepancy are not clear but several factors may be involved. Firstly detachment of 131I from the antibody may occur. Approximately 25% of the injected radioactivity was excreted via the kidneys in the first 3 days which since all patients had apparently normal renal function must represent free iodine.
Secondly the mouse monoclonal antibody may evoke a response in the recipient possibly through the immune system. There is already evidence that patients can develop antimouse antibodies (Pimm et al., 1985b ) and these may inactivate or modify the administered antibody. Alternatively antibody may become non specifically attached to circulating cellular components. Whatever the mechanism such modification would not only influence reactivity with tumour bound CEA but also would affect the reaction in the ELISA used to estimate antibody concentration. Thus the ELISA may not represent an accurate assessment of the serum or tissue antibody levels. Further work is in progress to evaluate any modifications in the antibody and alternative methods of determining antibody concentrations.
The technique of tumour localisation by labelled antibodies has great potential in the assessment of malignant disease. In this study uptake by primary and secondary deposits has been demonstrated. However, the absolute amount of labelled preparation accumulated is insufflcient to allow accurate tumour detection and thus limits the widespread use of the technique in clinical practice.
Further work. with particular reference to the pharmacokinetics of labelled antibodies is required to determine whether these difficulties can be overcome before the technique can be evaluated in independent clinical trials.
